Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Azelaic Acid Gel

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-626-52 D-0731-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-68 D-0738-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-68 D-0737-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Recalls by year